TABLE 5.

Risk factors of non-remission in PMN determined by univariate and multivariate Cox regression.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Gender
Female
Male	2.76 (1.15,6.63)	0.023	3.25 (1.11,9.51)	0.031
Age
<55 years
≥55 years	1.03 (0.54,1.95)	0.936	1.21 (0.58,2.51)	0.618
MBP	0.99 (0.96,1.02)	0.395	0.99 (0.96,1.02)	0.435
Serum anti-PLA2R Ab
<20 RU/ml
≥20 RU/ml	1.33 (0.58,3.03)	0.500	1.41 (0.67,3.01)	0.51
UP
≤8 g/day
>8 g/day	0.97 (0.51,1.85)	0.934	1.42 (0.67,3.01)	0.359
Follow-up 25(OH)D
Group 1 (<39.2)	19.16 (4.56,80.54)	<0.001	17.52 (4.04,76.03)	<0.001
Group 2 (39.2–62.3)	4.97 (1.07,23.08)	0.041	4.90 (1.02,23.53)	0.047
Group 3 (≥62.3)	Reference	1	Reference	1
Serum albumin	0.91 (0.84,0.98)	0.023	0.98 (0.89,1.08)	0.692
TC	0.93 (0.80,1.07)	0.307
HDL	0.75 (0.33,1.72)	0.494
LDL	0.84 (0.68,1.05)	0.126
eGFR	0.99 (0.98,1.00)	0.108
Serum IgG	0.89 (0.75,1.06)	0.182
Serum C3	0.12 (0.03,0.55)	0.006	0.20 (0.04,1.15)	0.072
Serum C4	0.53 (0.01,40.17)	0.773

Multivariate analysis was adjusted for age, gender, MBP, 24-h urinary protein, serum anti-PLA2R Ab, serum albumin, and serum C3. MBP, mean blood pressure; Anti-PLA2R Ab, anti-phospholipase A2 receptor antibody; UP, urinary protein; TC, serum total cholesterol; HDL-C, serum high-density lipoprotein cholesterol; LDL-C, serum low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; IgG, serum immunoglobulin G; C3, serum complement 3; C4, serum complement 4. Bold values denote statistical significance at the P < 0.05 level.